In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material. Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids. Owing to their ability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules, liposomes are extensively used as efficient delivery systems for antigens or drugs. Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.
Players Offering Liposome Development and Manufacturing Services
Presently, over 70 companies are actively engaged in offering services related to liposomes development and manufacturing, worldwide. Around 75% of the players offer services for liposome formulation development, followed by the players which offer analytical method development (65%) and contract manufacturing services (64%). Further, most of the liposome development and manufacturing service providers (68%) offer services for discovery / research purposes.
Till date, close to 800 clinical studies evaluating various liposome-based therapeutics have been initiated worldwide. Further, the most targeted disease area within oncological disorders is ovarian cancer, with 226 clinical trials registered in the given time period.
Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field
Over the years, there has been a gradual increase in the number of publications related to liposomes. Majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy. This can be attributed to the fact that liposomes can actively target tumor tissues when used in combination with antibodies.
High Number of Patents are Suggestive of the Widespread Research in this Domain
Several industry and non-industry players are involved in the development and manufacturing of liposomes in order to evaluate their therapeutic and diagnostic potential in the treatment of various diseases. The field has seen a significant rise in the number of patents over the past few years, majority (53.5%) of these patents are applications (not having received approval yet), followed by granted patents (46.2%).
Events related to Liposome Development and Manufacturing, organized Globally
In the past few years, various types of events (webinars / conferences / seminars / workshops / symposiums / summits) were organized to discuss the potential of liposomes as novel drug delivery systems. These platforms have created an opportunity for the product developers to share their innovative ideas in this domain.
Future Evolution of Liposome Development and Manufacturing Services Market
With the rising demand for novel therapeutic modalities, the liposome development and manufacturing services market is anticipated to grow at an annualized rate of around 10% between 2022 and 2035.
Despite several advancements, there are various challenges in development of liposomes, for which stakeholders are leveraging the expertise of various contract service providers offering development and manufacturing services. These service providers are actively upgrading their capabilities and infrastructure to accommodate the demand for these vesicles. Driven by the growing research efforts, development of advanced methods for preparation and characterization of liposomes, and efforts of various stakeholders, this segment of industry is likely to witness noteworthy growth in the foreseen future.